PRECLINICAL ASSESSMENT OF MONOCLONAL ANTIBODIES

Information

• Research Project
• 3614173

• ApplicationId

  3614173

• Core Project Number

  N01CM067719

• Full Project Number

  N01CM067719-000

• Serial Number

  67719

• FOA Number

• Sub Project Id

• Project Start Date

  2/1/1986 - 38 years ago

• Project End Date

  1/31/1989 - 35 years ago

• Program Officer Name

• Budget Start Date

  2/1/1986 - 38 years ago

• Budget End Date

  1/31/1987 - 37 years ago

• Fiscal Year

  1986

• Support Year

• Suffix

• Award Notice Date

  -

Organizations

• NEORX CORPORATION

To develop a coordinated program for uniform preclinical testing and evaluation of monoclonal antibodies and immunoconjugates (drugs, toxins, radioisotopes) in several test systems prior to entry into clinical trials. Monoclonal antibodies submitted for evaluation under this contract will have been subjected to a minimum level of characterization and been shown to have at least one of the following characteristics: 1 Specificity against a defined molecule (a growth factor), but need not necessarily have been characterized by immunohistochemistry. Features indicating ptoential usefulness as a tumor marker by immunoassay. Specificity for tumors by preliminary immunohistological testing against major human organs (spleen, liver, kidney). It is anticipated that 20 to 30 monoclonal antibody preparations will be evaluated annually by immunofluorescent and/or immunoperoxidase histochemistry.

IC Name

• Activity

  N01

• Administering IC

  CM

• Application Type

  1

• Direct Cost Amount

• Indirect Cost Amount

• Total Cost

• Sub Project Total Cost

• ARRA Funded

• CFDA Code

  395

• Ed Inst. Type

• Funding ICs

• Funding Mechanism

• Study Section

• Study Section Name

• Organization Name

  NEORX CORPORATION

• Organization Department

• Organization DUNS

• Organization City

  SEATTLE

• Organization State

  WA

• Organization Country

  UNITED STATES

• Organization Zip Code

  98119

• Organization District

  UNITED STATES